StockNow
Calendar
Log in
U.S. Markets

FDA approves belzutifan (MRK) in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component

StockNow breaking-news AI analysis

The FDA approved Merck's belzutifan combined with lenvatinib for treating advanced renal cell carcinoma with a clear cell component.

1 stocks
MRKMerck & Co., Inc.$147.95Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

[MARKET UPDATE]: Crude tumbles, Dollar sold, Stocks, Bonds and Gold rally on reports US and Iran discussing phased deal to reopen Strait of Hormuz and end US blockade

Geopolitics

Iran’s president says Tehran wants a deal with US before midterm elections, NBC reports

Politics

US President Trump welcomes Chinese President Xi to the White House; describes his relationship with Xi as "truly great"